MMP9 and triple-A syndrome: Incubation of human AAA explants with rivaroxaban in vitro has been reported to improve aortic wall mitochondrial function, reduce expression of markers of mitophagy, reduce expression of matrix metalloproteinase-9, and limit release of interleukin-6, which have all been implicated in AAA growth [19,20].